These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 15844767

  • 1. [Prognostic value of serum beta2-microglobulin in multiple myeloma].
    Bettini R, Redaelli S, Maino C, Bertuol S, Costantini C, Lazzarini A, Brivio L, Gorini M.
    Recenti Prog Med; 2005 Feb; 96(2):81-6. PubMed ID: 15844767
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J.
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [Abstract] [Full Text] [Related]

  • 3. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1655-8. PubMed ID: 17935664
    [Abstract] [Full Text] [Related]

  • 4. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
    Scudla V, Budíková M, Fischerová E, Zadrazil J, Indrák K.
    Acta Univ Palacki Olomuc Fac Med; 1991 Oct 05; 130():201-12. PubMed ID: 1838869
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
    Scudla V, Zemanova M, Minarik J, Bacovsky J, Ordeltova M, Indrak K, Budikova M, Dusek L, Farbiakova V.
    Neoplasma; 2006 Oct 05; 53(4):277-84. PubMed ID: 16830053
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. International staging system for multiple myeloma.
    Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J.
    J Clin Oncol; 2005 May 20; 23(15):3412-20. PubMed ID: 15809451
    [Abstract] [Full Text] [Related]

  • 9. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.
    Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696
    [Abstract] [Full Text] [Related]

  • 10. Simple prognostic model for patients with multiple myeloma: a single-center study in Japan.
    Kaneko M, Kanda Y, Oshima K, Nannya Y, Suguro M, Yamamoto R, Chizuka A, Hamaki T, Matsuyama T, Takezako N, Miwa A, Togawa A.
    Ann Hematol; 2002 Jan 15; 81(1):33-6. PubMed ID: 11807633
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.
    Delgado J, Pratt G, Phillips N, Briones J, Fegan C, Nomdedeu J, Pepper C, Aventin A, Ayats R, Brunet S, Martino R, Valcarcel D, Milligan D, Sierra J.
    Br J Haematol; 2009 Jun 15; 145(6):801-5. PubMed ID: 19388937
    [Abstract] [Full Text] [Related]

  • 13. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F, Minoia C, Favoino E, Prete M, Dammacco F.
    Blood Cells Mol Dis; 2009 Jun 15; 42(1):71-6. PubMed ID: 18996035
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B, Czerw T, Holowiecka-Goral A, Giebel S, Wojnar J, Holowiecki J.
    Transplant Proc; 2007 Nov 15; 39(9):2893-7. PubMed ID: 18022010
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Spicka I, Cieslar P, Procházka B, Jirsa M, Chrz M, Gregora E, Klener P.
    Cas Lek Cesk; 2000 Apr 12; 139(7):208-12. PubMed ID: 10916207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.